An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study
Abstract Objective Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastati...
Saved in:
Published in | Japanese journal of clinical oncology Vol. 51; no. 3; pp. 484 - 491 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
03.03.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!